Skip to main content
OpenTrials
Completed

NCT Number: NCT04590768

Tolerance of Regular Meal Intake With Mycoprotein (TOMMY)

This study aims to assess the impact of daily intake of 11 grams of Fermotein™ on gastrointestinal complaints and several other health related biomarkers. Furthermore, consumer acceptance is investigated. The study has a randomized parallel design. Two different treatments will be evaluated e.g. a 18-day intervention with fermotein based meals and a 18-day intervention with control meals. At the start and at the end of the intervention, a blood sample will be collected. Questionnaires about gut complaints, stool consistency and frequency, wellbeing, health complaints or other adverse effects will be collected daily during intervention and up to two days after the intervention.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stichting Wageningen Research

Wageningen, Gelderland, 6708 WG, Netherlands

About this study

Fermotein™ is a mycoprotein, derived from fungi, especially produced for human consumption. It is high in protein, high in fiber, low in saturated fat and contains no cholesterol. Its functional properties and nutrient content makes them ideal to use as an ingredient for meat alternatives and other vegetarian/vegan food products. This study aims to assess the impact of frequent intake of 11 grams of Fermotein™ powder (dry) on gastrointestinal complaints and several other health related biomarkers.

The primary objective is to investigate gastro-intestinal complaints during 18 days of Fermotein™ consumption. The secondary objective is to assess blood based parameters related to general health and consumer acceptance.

The study has a randomized parallel design. Two different treatments will be evaluated e.g. a 18-day intervention with Fermotein™ based meals and a 18-day intervention with control meals. At the start and at the end of the intervention a blood sample will be collected. Questionnaires about gut complaints, stool consistency and frequency, wellbeing, health complaints or other adverse effects will be collected daily during intervention and up to two days after the intervention.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Apparently healthy men and women (based on questionnaire)
  • Age between 18 and 70 years
  • Body mass index (BMI) between 18.5 and 29.9 kg/m2

Exclusion criteria

  • Any metabolic, gastrointestinal, inflammatory or chronic disease (such as diabetes, anaemia, hepatitis, cardiovascular disease), judged by the medical doctor
  • History of gastro-intestinal surgery or having (serious) gastro-intestinal complaints
  • History of liver dysfunction (cirrhosis, hepatitis)
  • Kidney dysfunction (self reported)
  • Use of medication that may influence the study results, such as gastric acid inhibitors or laxatives
  • Reported slimming or medically prescribed diet
  • Current smokers
  • Alcohol intake over 4 glasses of alcoholic beverages per day
  • Pregnant, lactating or wishing to become pregnant in the period of the study (self-reported)
  • Abuse of illicit drugs
  • Having food allergies
  • Participation in another clinical trial at the same time
  • Being an employee of the department Consumer Science and Health group of Wageningen Food and Biobased Research

Treatment and study plan

Fermotein based meals

Other

various meal products: bread, soup and an occasional burgers

Matching control meals with whey protein and wheat bran

Other

various meal products: bread, soup and an occasional burgers

Primary outcomes

  1. Change in gastro intestinal (GI) complaints

    Time frame: Daily, during 18 days of Fermotein™ intake and up to three days after intake.

    Determined by combining multiple outcome measures ( bloated feeling, belching, abdominal pain, flatulence, nausea, diarrhoea, constipation) measured via questionnaires with Visual Analogue Scale (VAS) scores; from no complaints (minimal) to serious complaints (maximum). Higher values represent a worse outcome.

Secondary outcomes

  1. change in blood hemoglobin

    Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption

    under fasting conditions

  2. change in blood Fe (iron)

    Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption

    under fasting conditions

  3. change in blood ferritin

    Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption

    under fasting conditions

  4. change in blood insulin

    Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption

    under fasting conditions

  5. change in blood glucose

    Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption

    under fasting conditions

  6. change in blood cholesterol (total)

    Time frame: before and after 18 days consumption of Fermotein™ or control product

    under fasting conditions

  7. change in blood ALAT

    Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption

    under fasting conditions

  8. change in blood ASAT

    Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption

    under fasting conditions

  9. change in blood GGT

    Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption

    under fasting conditions

  10. change in blood leukocyte cell counts

    Time frame: at baseline, and after 18 days of fermotein or control product consumption

    under fasting conditions

  11. change in blood creatinine

    Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption

    under fasting conditions

  12. change in blood zonulin

    Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption

    under fasting conditions

  13. change in blood pressure

    Time frame: at baseline, and after 18 days of Fermotein™ or control product consumption

    systolic and diastolic bloodpressure

Sponsors and collaborators

Lead sponsor

Wageningen University and Research

Other

Collaborators

  • The Protein Brewery

Registry information

Official study title

Tolerance of Regular Meal Intake With Mycoprotein

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Oct 19, 2020
Registry last updated
Jan 20, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.